Par Pharmaceutical Companies Inc. ("Par Pharma") is a U.S.-based specialty pharmaceutical company that develops, manufactures and markets high-barrier-to-entry generic drugs and niche, innovative proprietary pharmaceuticals.

According to the law firm press release, the Complaint charges Par Pharma and its Board and TPG with violations of the 1934 Act.

The Complaint alleges that Defendants failed to disclose material information in a proxy statement filed with the SEC and publicly disseminated in connection with the proposed sale of Par Pharma to TPG. According to the Complaint, the proxy statement was materially false and misleading because it made numerous material omissions about the process leading up to the agreement between Par Pharma and TPG and the work performed by Par Pharma’s financial advisor, J.P. Morgan Securities LLC, which was retained by Par Pharma to evaluate the fairness of TPG’s offer.

On October 19, 2012, the Court issued an Order consolidating cases.

On December 20, 2012, Plaintiff filed Notice voluntarily dismissing this Consolidated Action.